{"entity":{"id":"nct05168566","kind":"trial","name":"Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of Sutetinib Maleate Capsule in non-small-cell lung cancer, run by Teligene US, now recruiting.","summary":"Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05168566 by Teligene US, with 99 participants planned, started 2022-09-01 and due to reach its primary completion in 2027-12. Interventions recorded: Sutetinib Maleate Capsule.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05168566","url":"https://clinicaltrials.gov/study/NCT05168566"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05168566-j-thorac-oncol-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05168566","phase":"2","setting":"A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)","sponsor":"Teligene US","started":"2022-09-01","startedType":"actual","enrolled":99,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05168566/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"paper":[{"id":"paper-nct05168566-j-thorac-oncol-2026","kind":"paper","name":"Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial","route":"/key-papers/paper-nct05168566-j-thorac-oncol-2026/"}]}}